Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
Phase 3negativeTNX-103Negative
AI Analysis
Summary
Tenax Therapeutics' Phase 3 LEVEL trial for TNX-103 missed its primary endpoint. This is a significant negative development for the company's clinical program.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Primary endpoint missed
Importance:8/10
Sentiment:
-0.90
Phase 3 failuremissed primary endpointclinical trialTNX-103
Related Companies
Read the original article
Published by yahoo_finance on August 10, 2026 3:03 PM